Petrelintide

Petrelintide (ZP8396)

Evidence & Status

  • Moderate

Overview

Petrelintide (formerly ZP8396) is an investigational long-acting amylin analog studied for weight management. Randomized human studies evaluated once-weekly subcutaneous administration, pharmacokinetics, tolerability and effects on body weight. It remains investigational and is not FDA-approved.

Research Summary

Two randomized, placebo-controlled, double-blind Phase 1 trials evaluated petrelintide. The studies reported an approximately 10-day half-life, body-weight reduction of up to 8.6% after 16 weeks in the studied population, and gastrointestinal disorders as the most common treatment-emergent adverse events, mostly mild. No serious or severe treatment-emergent adverse events were reported, although one participant discontinued because of gastrointestinal adverse events; these early findings do not establish long-term safety or efficacy.

Research Areas

  • Weight management
  • Amylin biology
  • Metabolic research

Safety & Risks

Reported Side Effects

  • Gastrointestinal disorders, mostly mild, were the most common treatment-emergent adverse events in the published Phase 1 trials
United States
Investigational; not FDA-approved
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources